NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025. RxSight describes itself as a "commercial-stage medical technology company, engaged in the research and development, manufacture, and sale of light adjustable intraocular lenses.†For more information, submit a form, email attorney Phillip Kim, or gi. ...

Group 1 - RxSight, Inc. is under investigation for potential securities fraud claims following significant declines in sales and revenue [1][2] - The company reported a 37% drop in share price, closing at $7.95 per share after disclosing adoption challenges affecting LDD sales and LAL utilization [2] - Investors who acquired RxSight stock between November 7, 2024, and July 8, 2025, may seek lead plaintiff status in the ongoing litigation [3] Group 2 - RxSight specializes in medical technology, specifically developing light adjustable intraocular lenses (LAL) for cataract surgery [1] - The company's Light Delivery Device (LDD) is a key component of its RxSight system [1]

Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. for alleged securities fraud affecting investors between November 7, 2024, and July 8, 2025 [1][2]. Group 1: Allegations and Company Performance - The lawsuit claims that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is alleged that the company overstated the demand for its products, which resulted in an inability to meet previously issued financial guidance for fiscal year 2025 [2]. - The positive statements made by the defendants regarding the company's business and prospects were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - RxSight, Inc. specializes in manufacturing and selling light adjustable intraocular lenses for cataract surgery, with its main product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Financial Performance and Issues - During the relevant period, RxSight promoted strong sales of its LAL and Light Delivery Device (LDD) but failed to disclose "adoption challenges" and a slowdown in LAL utilization that began in 2024 [4]. - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast due to a "softening" market, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - On July 8, 2025, the company further lowered its revenue forecast, attributing it to slower LAL utilization and adoption challenges, resulting in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from November 7, 2024, to July 8, 2025, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 22, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that RxSight made false and misleading statements regarding its sales and utilization, overstated demand for its products, and was unlikely to meet its financial guidance for fiscal year 2025 [4]. - The misleading statements led to investor damages when the true details about the company's performance were revealed [4].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against RxSight, Inc. for allegedly misleading shareholders regarding the company's performance and financial guidance during a specified class period [2][4]. Summary by Relevant Sections Allegations - The complaint claims that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is alleged that the company overstated the demand for its products [2]. - As a result of these issues, RxSight is unlikely to meet its previously issued financial guidance for fiscal year 2025 [2]. - The positive statements made by the defendants about the company's business and prospects were materially misleading and lacked a reasonable basis [2]. Class Period and Deadlines - The class period for the lawsuit is from November 7, 2024, to July 8, 2025 [2]. - Shareholders are encouraged to register for the class action by September 22, 2025, to be eligible for potential recovery [3]. Next Steps for Shareholders - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased RxSight securities between November 7, 2024, and July 8, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 22, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Allegations Against RxSight - The lawsuit alleges that throughout the Class Period, RxSight's management made false and misleading statements regarding the company's sales and product demand, which ultimately misled investors [5]. - Specific claims include that RxSight faced "adoption challenges" and structural issues leading to declines in sales, and that the company was unlikely to meet its previously issued financial guidance for fiscal year 2025 [5].

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines [1][4][5]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that RxSight overstated the demand for its products, which contributed to the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second-quarter financial results on July 8, 2025, which showed significant declines in Light Delivery Device (LDD) sales and overall revenue, RxSight lowered its full-year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The announcement of the lowered guidance and the challenges faced by RxSight led to a nearly 38% drop in the company's stock price [5].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - RxSight, Inc. specializes in the manufacture and sale of light adjustable intraocular lenses used in cataract surgery, with its main product being the Light Adjustable Lens (LAL) [3]. Financial Performance and Issues - The company previously reported strong sales of LAL and Light Delivery Devices (LDD) but failed to disclose "adoption challenges" and a slowdown in LAL utilization that began in 2024 [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast due to a "softening" market, leading to a stock price decline of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut occurred on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulting in another 38% drop in stock price, from $12.79 to $7.95 per share [6].

Accessibility StatementSkip Navigation SAN DIEGO, Sept. 9, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the RxSight class action lawsuit – captioned Makaveev v. RxSight, Inc., No. 25-cv-01596 (C.D. Cal.) – seeks to represent purchasers or acquirers of RxSight, Inc. (NASDAQ: RXST) securities and charges RxSight as well as certain of RxSight's executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead ...